MD Medical Group IPJSC (“MD Medical”, "Group" or the "Company"; MOEX: MDMG), a leading Russian private healthcare provider, announces its operating and unaudited financial results for Q1 2025.

Key financial highlights for Q1 2025:

• Total revenue increased by 16.9% to RUB 8,956 million.

• Revenue of the Group’s hospitals in Moscow rose by 14.9% y-o-y to RUB 4,430 million due to strong demand for out-patient diagnostics, obstetrics, gynaecology, physiotherapy and rehabilitation services, growth in revenue from deliveries, as well as higher revenue from in-patient treatments mainly stemming from robust performance in the surgery segment.

• Revenue of the Group’s regional hospitals grew by 18.0% y-o-y to RUB 2,390 million driven primarily by revenue from in-patient oncology, plastic surgery, gynaecology and traumatology treatments.

• Revenue from out-patient clinics in Moscow and the Moscow Region rose by 25.1% y-o-y to RUB 882 million on the back of growing demand for the services provided by different categories of healthcare professionals, including at new clinics opened in 2024.

• Revenue from out-patient clinics in other regions rose by 15.2% y-o-y to RUB 1,225 million driven by stronger demand for out-patient treatments, including at new clinics opened in 2024.

• As at the end of Q1 2025, the Group’s cash position stood at RUB 8,260 million, with no debt financing raised by the Company.

• In Q1 2025, total Capex was RUB 616 million.

Key operational highlights for Q1 2025:

• Total out-patient treatments increased by 10.9% y-o-y to 628,876, with the average ticket up 13.4% to RUB 6.8 thousand in Moscow and up 9.4% y-o-y to RUB 2.7 thousand in other regions.

• Total IVF punctures went up by 8.3% y-o-y to 4,799, with the average ticket up 10.5% to RUB 335.5 thousand in Moscow and up 7.0% y-o-y to RUB 305.4 thousand in other regions.

• Total deliveries increased by 7.3% y-o-y to 2,796, with the average ticket up 12.7% y-o-y to RUB 620.3 thousand in Moscow and up 9.2% y-o-y to RUB 240.1 thousand in other regions.

• Total in-patient treatments decreased by 5.7% y-o-y to 36,463 despite a 6.5% uptick in surgeries, with the average in-patient care ticket up 19.5% y-o-y to RUB 122.0 thousand in Moscow and up 19.1% y-o-y to RUB 47.9 thousand in other regions.

Key events during Q1 2025 and after the reporting period:

• Launch of robotic surgery in two of the Group’s hospitals. In April 2025, the Group’s Lapino and Avicenna hospitals began working with the da Vinci robotic system. This advanced technology enables doctors to complete surgical treatments with minimal damage to surrounding tissues, thus significantly reducing the patients’ recovery time.

• Board of Directors recommends dividends for 2024. At its meeting on 28 March 2025, the Board of Directors resolved to recommend that,  in addition to dividends paid for the first three, six, and nine months of 2024, the General Meeting of Shareholders approve a dividend payment of RUB 1.7 billion, or RUB 22 per ordinary share of MD Medical Group (before dividend income tax) for the twelve months of 2024. Total dividends for 2024 are expected to exceed 60% of the Group's consolidated net profit for 2024 under IFRS.

• Expansion of the clinic in Mytishchi. On 28 March 2025 “Mother and Child Mytishchi” Women's Center began servicing patients at additional area. Expansion of the area will increase the patient flow and capacity of the Group's popular clinic from 24 thousand to 48 thousand visits per year. Investments in the clinic expansion amounted to RUB 18.5 mln.

• Opening of an IVF center on the basis of the Syktyvkar clinic. On 25 March 2025 the Group opened the IVF center on the basis of the Syktyvkar clinic acquired last June, where an important stage in the clinic's development was the addition of the Group’s competencies in reproductive technologies. The capacity of the IVF center, which occupies 310 sq m of the clinic, is designed for 800 IVF cycles per year. The total investment in the renovation and equipment of the IVF center amounted to RUB 80 million.

• The Company’s shares are included in the Moscow Exchange Index. Starting from 21 March 2025 MD Medical Group IPJSC ordinary shares are included in the Moscow Exchange Index and RTS Index calculation bases

• Expansion of the clinic in Odintsovo. On 26 February 2025 launched in 2016, the out-patient clinic in Odintsovo has now moved to a new, spacious three-storey building covering an area of 1,094 sq m. This expansion has increased the clinic's capacity from 30,000 to 120,000 visits per year. The total investment to cover its opening and equipment amounted to RUB 202.5 million.

• New clinic in Khabarovsk launch – expansion to new region. On 30 January 2025 the Group opened Mother & Child Khabarovsk clinic. Spanning 560 sq m, the facility will offer a wide range of specialised services for women in obstetrics, gynaecology, oncology, and reproductive medicine. The new clinic is designed to accommodate 30,000 visits and 800 IVF cycles per year. The cllinic has received a total investment of RUB 113 million for its opening and outfitting.

• New clinic in Krasnogorsk of Moscow region launch. On 16 January 2025 the Group opened Mother & Child Krasnogorsk clinic with a total area of 242 sq m which offers a wide range of specialized services for women. The capacity of the clinic allows for 36,000 outpatient visits per year. Total investments in the project came in at RUB 44 million.

MD Medical CEO Mark Kurtser said:

“The Company’s Q1 results showed significant momentum. Given the exceptionally strong performance we delivered last year, maintaining and building on that success was no small feat, and I am genuinely proud that we stood up to this challenge.

Compared to Q1 2024, revenue from our medical facilities in the Moscow Region and other regions where we operate grew at double-digit rates. Revenue from out-patient treatments rose by 23%, confirming the strong demand for our out-patient services, a segment we have been actively developing over the past two years by investing in new clinic openings and acquisitions and by expanding the range of treatments available at hospitals. In Q1 2025, more and more patients turned to our diagnostic and treatment centres, as accurate and timely diagnostics are becoming increasingly important today. High occupancy rates in obstetrics and gynaecology were among the key drivers of a 19% increase in revenue from deliveries. Revenue growth in IVF came in at 18%.

In the reporting quarter, we saw a 10% increase in revenue from in-patient treatments driven by sophisticated surgeries in traumatology, gynaecology and cardiology; the launch of nephrology as a new specialty at the Lapino Clinical Hospital; and growing demand for chemotherapy treatments.

With a stable operating cash flow and no debt on the balance sheet, we are in a strong position to invest in expanding our capabilities this year. This includes purchasing cutting-edge surgical equipment, launching new lines of treatment in our hospitals, and expanding the network of our medical facilities. Similarly to previous periods, we plan to allocate no less than 60% of net profit to dividends distributed at least twice a year.”

Notes:
1.     Data is based on management accounts
2.     Minor variations in calculation of totals, subtotals and/or percentage change are due to rounding of decimals

***

About MD Medical Group

MD Medical Group is a leading provider in the highly attractive Russian private healthcare service market. Today, the Company manages 65 state-of-the-art healthcare facilities, including 11 multidisciplinary hospitals and 54 out-patient clinics in 31 regions of the Russian Federation. In 2024, MD Medical Group's revenue amounted to RUB 33.1 bln. while EBITDA stood at RUB 10.7 bln, The Company's ordinary shares are traded on Moscow Exchange (MOEX: MDMG).